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White coat hypertension (WCH) describes a 
blood pressure (BP) phenotype present in 
untreated individuals with elevated clinic BP, but 
normal out-of-office values. There has been a 
growing recognition of this phenomenon since it 
was first noted over three decades ago, and it now 
features in both national and international hyper-
tension guidelines.1–4 Despite this, there are con-
siderable gaps in our understanding of WCH. It is 
still not clear what risk is conferred by WCH and 
whether it warrants treatment.
WCH is an important phenomenon to understand 
because it is a proposed risk factor for the develop-
ment of sustained hypertension (SH), target organ 
damage (TOD) and possibly the occurrence cardio-
vascular (CV) events. Recently, WCH has been 
found to increase the relative risk of sustained 
hypertension by almost three-fold when compared 
with patients with normal BP.5 Furthermore, WCH 
can lead to impairment of myocardial function and, 
compared with normotensive patients, there is an 
increased risk of carotid atherosclerosis.6,7 The asso-
ciation between WCH and CV events is considera-
bly less clear. Some evidence suggests that WCH is 
an intermediate risk category positioned somewhere 
between those with normotension and sustained 
hypertension.8,9 This is in contrast to other studies, 
which have found that patients with WCH do not 
have additional CV risk.10,11 This apparent lack of 
clarity deserves further investigation.
The dearth of randomised controlled trial data on 
WCH has led to inference of results from sub-
group analyses performed in patients with numer-
ous forms of hypertension. These types of analyses 
have yielded controversial results. Some studies 
are in favour of the treatment of WCH, whilst 
others suggest that treatment benefits only those 
with sustained hypertension.12,13 Based on this 
limited evidence, the European Society of 
Hypertension (ESH) has developed guidelines for 
the treatment of WCH. They suggest that patients 
with WCH and no additional CV risk factors 
should be managed with lifestyle changes and 
closely followed due to their increased risk of 
developing SH and TOD. In individuals with 
WCH and evidence of hypertension-mediated 
organ damage or elevated CV risk, it may be 
appropriate to offer recommendations on lifestyle 
changes in conjunction with drug treatment.3
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Definition
WCH describes an elevated clinic BP in the pres-
ence of normal out-of-office BP values. This BP 
phenotype is also referred to as white coat syn-
drome. The ESH suggest that patients with an 
office reading of at least 140/90 mmHg and a 
mean 24-h BP of less than 130/80 mmHg are 
deemed to have WCH.14 This differs from the 
original definition by Pickering et  al., as it uses 
24-h rather than day-time ambulatory BP moni-
toring.1 This updated definition may be prefera-
ble as it includes night-time BP, which has been 
shown to be a stronger predictor of outcomes 
than day-time BP.15 The ESH guidance also 
states that the term WCH should be reserved for 
untreated individuals only. This is in contrast to 
the white coat effect, which describes the differ-
ence between an elevated clinic BP and a lower 
home or ambulatory BP in both untreated and 
treated patients.14 The white coat effect is consid-
ered clinically significant if the difference between 
clinic and out-of-office BP exceeds 20/10 mmHg.4
There is no universally accepted approach to 
investigate and define WCH. This is not unre-
lated to the various definitions of hypertension 
(Table 1). ESH, American College of Cardiology/
American Heart Association (ACC/AHA) and 
National Institute for Health and Care Excellence 
(NICE) guidelines all differ from one another 
in this regard (Table 2). ACC/AHA guidelines 
define WCH as a clinic BP of 130/80 mmHg or 
above, in the presence of day-time ambulatory or 
home BP less than 130/80 mmHg. Ambulatory 
and home BP monitoring (ABPM and HBPM 
respectively) are offered only when WCH is sus-
pected and following a 3-month intervention of 
lifestyle modification.4 In the NICE guidelines, 
ABPM or HBPM is offered to those with a clinic 
BP of 140/90 mmHg or higher. They are deemed 
to have WCH if day-time ambulatory or average 
home BP is below 135/85 mmHg.2 The lower 
threshold values in the ACC/AHA guidelines are 
due largely to the findings of the Systolic Blood 
Pressure Intervention Trial (SPRINT) study.16 
This showed that, in patients with systolic BP 
(SBP) > 130 mmHg and elevated CV risk with-
out diabetes, intensive BP treatment (target 
SBP < 120 mmHg) reduced CV events and all-
cause mortality compared with standard treat-
ment (target SBP < 140 mmHg). Importantly, 
the participants of this study were unattended 
during clinic BP measurement.17 These values are 
significantly lower than those obtained using con-
ventional observed BP measurement due to a 
reduction in the white coat effect.18 It has there-
fore been suggested that the BP values achieved 
in the SPRINT study, and subsequently reflected 
in the ACC/AHA guidelines, might be similar to 
the more conservative thresholds in the ESH and 
NICE guidelines.19
There are several explanations for the variation in 
how WCH is defined. Firstly, some individuals 
display a slight increase in clinic BP compared 
with 24-h ambulatory BP.20 It is therefore very 
difficult to assign a discrete cut-off value at which 
this elevation in clinic BP becomes pathological, 
and should therefore be considered WCH. 
Secondly, multiple comparators can be used 
when comparing clinic and out-of-clinic readings. 
These include home BP, day-time ambulatory 
BP, night-time BP and 24-h recordings. It is not 
yet clear which of these comparators are preferred 
for the identification of patients with WCH. 
Variability in the definition of WCH means that 
there is some heterogeneity in the subjects 
included in different studies. It is consequently 
more difficult to reach conclusions regarding the 
effects of WCH and its treatment.
Further variability in the identification of patients 
with WCH occurs due to the methods used to 
record BP. Poor clinic BP measurement tech-
nique such as insufficient patient rest time, 
crossed legs and small cuff size can lead to spuri-
ously elevated BP measurements that could 
mimic WCH.21 The diagnosis of WCH is also 
influenced by the number of BP recordings and 
the regression to the mean phenomenon. In 
patients classified as having stage 1 hypertension 
on initial clinic BP measurement (140–159/90–
99 mmHg), 35% fall to a lower BP category when 
a mean of the second and third clinic values is 
used.22 The same phenomenon occurs when BP 
is measured on multiple occasions. In a study of 
patients that initially met the criteria for WCH, 
mean clinic BP reduced from 146 to 135 mmHg 
and mean ABPM increased from 120 to 
125 mmHg at follow up.23
Epidemiology
The prevalence of WCH has been estimated at 
13% from meta-analysis of studies performed on 
treated and untreated subjects. This analysis used 
G Nuredini, A Saunders et al.
http://tac.sagepub.com 3
cut-off values of 140/90 mmHg for clinic BP and 
135/85 mmHg for out of clinic BP (83 mm Hg in 
one study) measured by either day-time ABPM 
or home BP.24 It should be noted that these cut-
off values and comparators are the same as those 
in the NICE guidelines, but differ from those in 
ESH and ACC/AHA guidelines. The Spanish 
Ambulatory BP Monitoring Registry has been 
used to assess the prevalence of WCH according 
to the ESH definition. Amongst patients with 
elevated clinic BP, 35% of untreated patients can 
be classified as having WCH.25 Prevalence esti-
mated in other studies is highly variable, ranging 
from 10% to 50% depending on the definition of 
WCH and the cohort studied.26 When we con-
sider these values, it is important to appreciate the 
low reproducibility of clinic BP measurements. 
When clinic and ambulatory BP recordings are 
taken at different timepoints, only 55% of indi-
viduals meet the criteria for WCH on both occa-
sions.27 The prevalence of WCH is not distributed 
equally across the population. Compared with 
normotensive patients, there is a preponderance 
of older age, male sex, obesity and elevated blood 
lipids in patients with WCH. This is the case 
regardless of the WCH definition used.25
Etiology
There are several proposed triggers for the onset 
of WCH and these occur throughout the process 
of recording clinic BP. Patients with WCH have a 
discrete elevation in BP on arrival at the doctor’s 
office and during manual BP recordings with a 
cuff and manometer. These elevations in BP 
exceed those recorded by ABPM during episodes 
of anxiety or aggravation.28 Public speaking is a 
frequently cited trigger for episodes of elevated 
BP. This has been tested by dividing a cohort of 
hypertensive patients into two groups based on 
whether their BP response to a doctor’s visit was 
above or below the median value. Individuals in 
Table 1. Current staging of hypertension by NICE, ESH/ESC and ACC/AHA. Adapted from NICE, ESH/ESC and 
ACC/AHA guidelines.2–4
Systolic BP (mmHg) Diastolic BP (mmHg)
NICE (2019)
Normotension <120 <80
Stage 1 Hypertension ⩾140 ⩾90
Stage 2 Hypertension ⩾160 ⩾100
Severe hypertension ⩾180 or ⩾120
ESH/ESC (2018)
Normotension <120 <80
Grade 1 Hypertension 140–159 and/or 90–99
Grade 2 Hypertension 160–179 and/or 100–109
Grade 3 hypertension ⩾180 and/or ⩾110
ACC/AHA (2017)
Normotension <120 and <80
Elevated BP 120–129 and <80
Stage 1 Hypertension 130–139 or 80–89
Stage 2 Hypertension ⩾140 or ⩾90
ACC, American College of Cardiology; AHA, American Heart Association; BP, blood pressure; ESC, European Society of 
Cardiology; ESH, European Society of Hypertension; NICE, National Institute for Health and Care Excellence.
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the former group showed greater BP reactivity to 
public speaking. Whilst this might demonstrate 
that BP in this patient group is susceptible to psy-
chosocial stressors, the trigger investigated is of 
little relevance in the real world.29 A greater 
emphasis on recognising triggers for spikes in BP 
could provide a means to attenuate WCH, and 
thus an individual’s need for treatment.
Psychological characteristics, particularly anxiety, 
might be responsible for the presence of WCH. 
Anxiety is an emerging risk factor for numerous 
CV diseases, but its role in WCH is less clear.30 
Levels of anxiety and other traits can be quanti-
fied using a personality inventory. In patients 
treated with anti-hypertensives, high levels of 
anxiety have been shown to increase the risk of 
pseudo-resistant hypertension due to the white 
coat effect.31 These findings are in contrast to ear-
lier work showing that psychological characteris-
tics do not differ between those with WCH and 
sustained hypertension.32 Clearly, this remains an 
area of contention. Others have investigated the 
role of anxiety during a visit to the doctor’s office, 
rather than as a personality trait. This has been 
done by using two different scales to measure 
patient anxiety and expectations concerning their 
BP outcomes. Both of these variables are posi-
tively associated with elevated clinic BP. This 
might suggest that a patient’s expectation of high 
BP provokes anxiety during the consultation, 
which causes a transient elevation in BP.33 This 
hypothesis is supported by the finding that simply 
placing a cuff around a patient’s arm and not 
inflating it or recording BP is sufficient to cause a 
peak in BP of the same magnitude as if a full man-
ual recording had been taken.28 Whilst these 
studies provide interesting insight into the psy-
chological determinants of WCH, more work is 
required to fully understand this relationship.
Pathophysiology
The sympathetic and endocrine systems have both 
been implicated in the genesis of WCH. This has 
been investigated by simultaneously measuring 
arterial BP, heart rate and postganglionic muscle 
and skin sympathetic nerve activity during a doc-
tor’s visit. Subjects displayed an elevation in both 
BP and heart rate during the visit. This was 
accompanied by an increase in skin sympathetic 
nerve traffic and a corresponding reduction in 
muscle sympathetic nerve traffic. With the excep-
tion of skin sympathetic nerve traffic, these 
changes endured for several minutes after the end 
of the visit.34 This early worked laid the founda-
tions for our current understanding of the patho-
physiology of WCH, but it must be stressed that it 
is based on just 10 patients with essential hyper-
tension. The same experiments have since been 
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repeated, confirming that a doctor’s visit changes 
these four parameters as previously noted. 
Interestingly, these repeat experiments show that 
a nurse’s visit provoked a significantly attenuated 
response compared with a doctor’s visit.35 The 
endocrine system may have an important role in 
the recovery of BP in the hours rather than min-
utes following a clinic visit. Hospital-initiated 
ABPM shows that BP takes 2–3 h to reach the 
usual day-time values. This could be explained by 
a prolonged sympathetic response or by some 
endocrine contribution.28 This hypothesis has yet 
to be investigated.
WCH and its significance in cardiovascular 
disease
WCH is well characterized in the medical literature, 
but there is not yet a consensus on its prognostic 
significance in cardiovascular disease (CVD). 
However, growing evidence has started to estab-
lish a link between WCH and risk factors associ-
ated with CVD, namely the development of SH 
and the presence of TOD. Both are important 
and independent predictors of CV risk.36,37
Sustained hypertension
In the Pressioni Arteriose Monitorate e Loro 
Associazioni (PAMELA) population, clinic BP 
and 24-h ABPM was used to stratify subjects into 
different blood pressure phenotypes.38 At base-
line, 758 were defined as true normotensives 
(normal clinic BP and ABPM), 225 had WCH 
(elevated clinic BP but normal ABPM) and 124 
were found to have masked hypertension (normal 
clinic BP but elevated ABPM). When these indi-
viduals were re-evaluated 10 years later, 136 pre-
viously normotensive (18.2%) and 95 previously 
white coat hypertensives (42.6%) had progressed 
to SH. The risk of transitioning to SH was 2.5-
fold greater for white coat hypertensives (HR 
2.51, CI 1.79–3.54, p < 0.0001) compared with 
normotensives. The same trend was observed 
when HBPM was used at baseline and follow up 
(HR 3.81, CI 2.57–5.64, p < 0.0001). The inves-
tigators found that the main predictor of pro-
gressing to SH was SBP at baseline. Interestingly, 
the rise in diastolic BP (DBP) was attenuated, 
leading to a more pronounced increase in pulse 
pressure. One may therefore postulate that the 
progression to SH may be due, in part, to stiffen-
ing of the larger arteries.38
An observational study of inhabitants of Ohasama 
(Japan) yielded similar results to the PAMELA 
population. At baseline, a total of 777 partici-
pants were recruited, of which 649 had sustained 
normotension (NT). The remaining 128 partici-
pants had WCH diagnosed with the use of 
HBPM. After an 8-year follow up, 22.2% of sub-
jects with sustained NT and 46.9% with WCH 
developed SH. The odds ratio (OR) for progress-
ing to SH was significantly higher in white coat 
hypertensives than normotensives (OR 2.86, 
p < 0.001).39 More recently, the results from the 
Finn-Home study further evaluated the risk of 
progressing from WCH to SH in the general pop-
ulation. Among the 528 normotensive partici-
pants at baseline, 96 (18.2%) developed SH after 
11 years. Of the 142 white coat hypertensives at 
baseline, 74 (52.1%) progressed to SH. The rela-
tive risk (RR) for progression from WCH to SH 
was 2.8 (95% CI 2.2–3.6, p < 0.0001).5
On the basis of these observations, it could be 
argued that WCH should be classified as a ‘pre-
hypertensive’ state, as individuals with WCH 
have increased risk of developing SH when com-
pared with the truly normotensive population.
Target organ damage
Myocardial infarction (MI) and ischaemic stroke 
are the main clinical manifestations of hyperten-
sive disease. However, in the sub-clinical phases, 
there is evidence of pre-existing organ damage. 
One of the most well described forms of TOD 
in relation to hypertension is left ventricular 
hypertrophy (LVH). Early findings from the 
Framingham Heart Study implicated LVH as a 
harbinger of CVD morbidity and mortality. Over 
a 4-year period, researchers found the incidence 
of CVD to be almost 2-fold greater in hyperten-
sive adults with LVH than without LVH. When 
adjusted for multivariate analysis, the presence of 
LVH increased the RR of CVD by 1.49 (95% CI 
1.20–1.85) in men and 1.57 (95% CI 1.20–2.04) 
in women.37 With this in mind, a recent meta-
analysis aimed to assess the impact of WCH on 
cardiac structure and function. A total of 7382 
individuals were included in the analysis from 25 
studies: 2493 were normotensive, 1705 had 
WCH and 3184 had SH. Clinic BP and ABPM 
was used to define each phenotype, with echocar-
diography being used to assess LV mass and func-
tion. Three major findings were reported: (i) left 
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ventricular mass index showed a graded, signifi-
cant increase from normotensive, white coat 
hypertensive to sustained hypertensive subjects. 
(ii) Pooled data from eight studies showed left 
ventricular diastolic function, as assessed by E/A 
ratio, to be highest in normotensives (1.17 ± 0.07, 
n = 337), lower in WCH (1.07 ± 0.07, n = 471) 
and lower still in SH (0.99 ± 0.11, n = 852). (iii) 
Five studies documented left atrial diameter in 
normotensives (3.26 ± 0.03 cm, n = 161), WCH 
(3.31 ± 0.11 cm, n = 193) and SH (3.44 ± 0.13 cm, 
n = 261). Left atrial diameter was significantly 
higher in WCH than in normotensive patients 
and in SH.40
Another index for assessing TOD is measuring 
the carotid intima-media thickness (CIMT). For 
many years, CIMT has been used in clinical prac-
tice as a surrogate marker for CVD. This is based 
largely on observational data that show a positive 
association between CIMT and the incidence of 
CVD. For example, in the Cardiovascular Health 
Study of 4476 individuals over the age of 65 and 
without pre-existing CVD, ultrasound sonogra-
phy was used to classify individuals into quintiles 
based on their CIMT. It was found that the inci-
dence of stroke or MI increased across quintiles.41 
Other studies show that CIMT is an independent 
predictor of future CV events.42,43 In the context 
of sustained hypertension, it is well known that 
CIMT is greater amongst hypertensives when 
compared with normotensive controls; however, 
much less is known about the relationship 
between WCH and CIMT.44–46 To date, only one 
meta-analysis has sought to address this issue. 
Of the 3478 untreated individuals included in 
this meta-analysis, 940 were normotensive, 666 
had WCH and 1872 had SH. CIMT showed 
a progressive increase from normotensive 
(718 ± 36 μm) to WCH (763 ± 47 μm, p < 0.01) 
and to hypertensive patients (817 ± 47 μm, 
p < 0.01).47 More recently, it has been found that 
patients with WCH had significantly higher mean 
CIMT than those with normotension (p < 0.05) 
and significantly lower than individuals with SH 
(p < 0.05). These results remained significant 
after adjusting for age and traditional CV risk fac-
tors such as smoking, diabetes mellitus and hyper-
cholesterolaemia.48 The overriding theme from 
the studies linking TOD and WCH seems to sug-
gest that WCH is an intermediate phenotype 
between NT and SH on the continuum of CV 
risk.
CV outcomes
Meta-analyses investigating untreated WCH and 
CV outcomes have yielded inconclusive results. 
In a recent study from Cohen et  al., untreated 
WCH was associated with an increased risk of CV 
events (HR 1.36, 95% CI 1.03–2.00) and CV 
mortality (HR 2.09, 95% CI 1.23–4.48) com-
pared with NT.49 No differences were observed 
when individuals with white coat uncontrolled 
hypertension (WCUH), also referred to as treated 
WCH or WCE, were compared with normoten-
sive subjects. This suggests that untreated WCH 
may confer higher CV risk than WCUH.49 In 
another meta-analysis by Huang et al. (n = 20,445, 
mean follow up 9.6 years), CVD was found to be 
significantly higher amongst untreated white coat 
hypertensives versus normotensives (RR 1.38, 
95% CI 1.15–1.65).12 This supports earlier find-
ings from an analysis of 29,100 participants 
(NT = 1538, WCH = 4806 and SH = 10,756) 
from across 14 studies, which concluded that 
white coat hypertensives had higher rates of CV 
morbidity and mortality versus those with NT 
(OR 1.73, 95% CI 1.27–2.36, p = 0.006).9
This view, however, is not unequivocal and is 
challenged by Pierdoemnico et  al., who pooled 
data from eight studies comprising 3050 normo-
tensives, 1279 white coat hypertensives and 3953 
sustained hypertensives. They found no differ-
ence in CV risk between WCH and NT, with an 
adjusted HR of 0.96 (95% CI 0.65–1.42) for 
WCH versus NT (p = 0.85) and 2.59 (95% CI 
2.0–3.35) for SH versus NT (p = 0.0001).11 
Another viewpoint which may clarify the disa-
greement in the literature has been presented by 
Franklin et  al.50 In their study of the IDACO 
database, 653 individuals with WCH were 
matched to a normotensive participant on the 
basis of age and CV risk profile. Low CV risk was 
defined as 0–2 risk factors, and high risk was 
defined as ⩾3 to 5 risk factors, diabetes and/or 
history of prior CVD events. After a median fol-
low up of 10.6 years, the incidence of CV events 
was comparable between low risk cohorts with 
NT and WCH (HR: 1.06; 95% CI: 0.66–1.72; 
p = 0.80). In contrast, the incidence of CV events 
was significantly higher when participants with 
high risk NT and WCH were compared (HR: 
2.06; 95% CI: 1.10–3.84; p = 0.023). This would 
suggest that age is not implicated in the associa-
tion between WCH and CV outcomes. Interest-
ingly, when the data was analysed further, the 
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excess in the number of CV events amongst WCH 
were confined to individuals above 60 years of age 
at baseline with concurrent high CV risk. This 
small group represented only 3.4% of the WCH 
population, leading the authors to hypothesise 
that these individuals may have had isolated sys-
tolic hypertension with WCE rather than WCH.50 
Discrepancies in how WCH was diagnosed, as 
well as the values used, could offer one explana-
tion to why there is a disagreement between 
analyses.
Treatment of WCH?
There is scarcity of large, prospective, randomised 
controlled trials (RCT) evaluating the effect of 
anti-hypertensive therapy on the incidence of cer-
ebrovascular and CV events in patients with 
WCH. Currently, there are only two RCTs, and 
each is a subgroup analysis of a larger trial. The 
first is a subgroup analysis of 695 participants 
from the Syst-Eur trial aged >60, with a clinic 
systolic central blood pressure (CBP) 160–
219 mmHg and a diastolic CBP < 90 mmHg.13 
Participants were divided into three groups based 
on their Systolic ABPM into: non-sustained 
hypertension (<140 mmHg), mild sustained 
hypertension (140–159 mmHg) or moderate sus-
tained hypertension (>160 mmHg). They were 
then randomised to receive anti-hypertensive 
therapy or a matching placebo. Active treatment 
significantly reduced clinic and ambulatory BP in 
patients with sustained hypertension, but reduced 
clinic BP only in those with non-sustained hyper-
tension. The most important finding from this 
study was that the incidence of stroke and CV 
events was lower in both sustained and non-sus-
tained treated hypertensive patients.
The second study was a subgroup analysis of the 
Hypertension in the Very Elderly Trial (HYVET), 
a double-blind randomised trial evaluating the 
efficacy of sustained release indapamide (1.5 mg) ± 
perindopril (2–4 mg) in elderly hypertensives who 
were over 80 years old and had a systolic BP 
between 160–199 mmHg. After a mean follow up 
period of 13 months, the difference in ABPM 
between the treatment and placebo arms was –8/–
5 mmHg. This translated into a reduction of 21% 
in total mortality and 34% in all CV events within 
the treatment arm. In a post hoc analysis, 50% 
(56, 95% CI 40–60%) of participants satisfied the 
criteria for WCH based on daytime ABPM.51 
The findings of the Syst-Eur and HYVET trials 
suggest that treating WCH in the over 60s and 
over 80s might confer some protection to future 
CV events, but they also need to be considered in 
the context of their limitations. Both are retro-
spective analyses of trials assessing anti-hyperten-
sive therapy in sustained hypertension. It would 
be preferable to draw upon data from trials assess-
ing anti-hypertensive therapy in WCH. In addi-
tion, the participants recruited were elderly, and 
are not representative of the whole population. 
Most importantly, the numbers of fatal and non-
fatal events are low, which limits statistical power 
and brings into question the reliability of their 
results.
Research gaps
WCH is an under researched phenotype of sus-
tained hypertension and there is still much to be 
discovered. Firstly, whether WCH is a benign 
phenomenon is unclear. This is due to a lack of 
observational data comparing CV morbidity and 
mortality between WCH and NT. The number of 
patients studied in the existing evidence base is 
currently too low, which would explain the con-
flicting results. Secondly, if we were to establish 
there was a need to treat WCH, we must also 
consider the economic and social implications. 
Amongst patients with sustained hypertension, 
approximately 80 patients would need to be 
treated with a first-line anti-hypertensive agent in 
order to prevent one death.52 Would it have the 
same benefits to treat that number for WCH? Do 
we need to treat those with white coat effect? 
What would be the best prescribed dose? The 
long-term sequelae of hypertension costs the UK 
health economy £2 billion per year.53 Would 
treating those with WCH prove to be cost effec-
tive? These are all important questions that need 
to be answered before 13% of the general popula-
tion is potentially medicalised.24 Thirdly, the 
existing definition of WCH is too rigid. It does 
not take into consideration the fact that WCH is 
not a static phenomenon and can fluctuate over 
time. For example, only 55% of individuals who 
are diagnosed with WCH fulfil the criteria over 
two visits.27 This is a problem as it brings into 
question who should be included for observa-
tional studies. Furthermore, a recent study sug-
gests that reproducibility over time is poor and 
this might present a challenge in the design of 
long-term prognostic studies.54 Finally, WCH 
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must be considered in the wider context of hyper-
tension itself. The recent SPRINT results dem-
onstrated that high-risk individuals who received 
intensive BP lowering of SBP < 120 mmHg, had 
significantly lower rates of primary composite 
outcomes (MI, acute coronary syndromes, heart 
failure), than those who received standard lower-
ing of SBP < 140 mmHg (1.65% versus 2.19% per 
year).16 These results have challenged our tradi-
tional view of treating hypertension and has led 
the ACC/AHA to call for more aggressive targets 
in BP control.4 If treatment thresholds and tar-
gets for hypertension change, this might have a 
ripple effect on the approach to WCH.
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